DPP4 and Hypoglycemia: These findings emphasize the necessity for careful selection of antidiabetic agents in this population, favoring those with a lower risk of hypoglycemia, such as DPP-4 inhibitors or SGLT2 inhibitors [14]. The recommendations from the 2023 AGS Beers Criteria regarding the medication classes identified as PIMs in our study are outlined in Table 4.